Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy

Ye, Yu; Akashi, Yoshimasa; Shimomura, Osamu; Tateno, Hiroaki; Saito, Sayoko; Hiemori, Keiko; Miyazaki, Yoshihiro; Furuta, Tomoaki; Kitaguchi, Daichi; Kuroda, Yukihito; Louphrasitthiphol, Pakavarin

doi:10.1007/s10120-022-01312-x

Cited by 8 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously demonstrated that our lectin‐based carrier system is also promising as a therapeutic strategy for pancreatic cancer. 27 , 29 Additional versatility against prostate, 60 gastric, 61 and colorectal cancers 53 reinforces its usefulness as a multispectrum therapy that exemplifies the potential of lectin development with regard to cancer screening and treatment. Future lectin engineering could simultaneously create similar dual‐use imaging and therapy molecules that exploit favorable reactivity to diverse organ and tissue malignancies, linking side chains and effector molecules to customize imaging/tumoricidal functions.…”

Section: Discussionmentioning

confidence: 90%

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: ¹⁸F‐labeled rBC2LCN lectin

et al. 2023

Self Cite

View full text Add to dashboard Cite

Advancement in early detection modalities will greatly improve the overall prognoses of pancreatic ductal adenocarcinoma (PDAC). For this purpose, we report a novel class of tumor-specific probes for positron emission tomography (PET) based on targeting cell surface glycans. The PDAC-targeting ability of rBC2LCN lectin, combined with fluorine-18 ( 18 F) ([ 18 F]FB-rBC2LCN), resulted in reproducible, high-contrast PET imaging of tumors in a PDAC xenograft mouse model. [ 18 F]N-succinimidyl-4fluorobenzoate ([ 18 F]SFB) was conjugated to rBC2LCN, and [ 18 F]FB-rBC2LCN was successfully prepared with a radiochemical purity >95%. Cell binding and uptake revealed that [ 18 F]FB-rBC2LCN binds to H-type-3-positive Capan-1 pancreatic cancer cells. As early as 60 min after [ 18 F]FB-rBC2LCN (0.34 ± 0.15 MBq) injection into the tail vein of nude mice subcutaneously bearing Capan-1 tumors, tumor uptake was high (6.6 ± 1.8 %ID/g), and the uptake increased over time (8.8 ± 1.9 %ID/g and 11 ± 3.2 %ID/g at 150 and 240 min after injection, respectively). Tumor-to-muscle ratios increased over time, up to 19 ± 1.8 at 360 min. High-contrast PET imaging of tumors relative to background muscle was also achieved as early as 60 min after injection of [ 18 F]FB-rBC2LCN (0.66 ± 0.12 MBq) and continued to increase up to 240 min.Our 18 F-labeled rBC2LCN lectin warrants further clinical development to improve the accuracy and sensitivity of early-stage pancreatic cancer detection.

show abstract

Section: Discussionmentioning

confidence: 90%

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: ¹⁸F‐labeled rBC2LCN lectin

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“… 25 , 26 , 27 Therefore, to circumvent restrictions from the relatively limited EGFR‐positive nature of PDAC, we previously reported rBC2LCN as a reactive lectin, 10 indicating that a lectin‐binding, fucosylated glycan epitope could be an attractive therapeutic target for PDAC. 8 , 28 , 29 Promisingly, rBC2LCN lectin has been recently shown to have positive reactivity to diverse cancers of differing tissue origins, 30 , 31 , 32 , 33 suggesting a potential, generalized application of rBC2‐IR700 when no cancer‐specific cell surface receptors or clinically approved antibodies are available.…”

Section: Discussionmentioning

confidence: 99%

Lectin‐based phototherapy targeting cell surface glycans for pancreatic cancer

Kuroda

Oda

Shimomura

et al. 2022

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is resistant to current treatments but lectin‐based therapy targeting cell surface glycans could be a promising new horizon. Here, we report a novel lectin‐based phototherapy (Lec‐PT) that combines the PDAC targeting ability of rBC2LCN lectin to a photoabsorber, IRDye700DX (rBC2‐IR700), resulting in a novel and highly specific near‐infrared, light‐activated, anti‐PDAC therapy. Lec‐PT cytotoxicity was first verified in vitro with a human PDAC cell line, Capan‐1, indicating that rBC2‐IR700 is only cytotoxic upon cellular binding and exposure to near‐infrared light. The therapeutic efficacy of Lec‐PT was subsequently verified in vivo using cell lines and patient‐derived, subcutaneous xenografting into nude mice. Significant accumulation of rBC2‐IR700 occurs as early as 2 hours postintravenous administration while cytotoxicity is only achieved upon exposure to near‐infrared light. Repeated treatments further slowed tumor growth. Lec‐PT was also assessed for off‐target toxicity in the orthotopic xenograft model. Shielding of intraperitoneal organs from near‐infrared light minimized off‐target toxicity. Using readily available components, Lec‐PT specifically targeted pancreatic cancer with high reproducibility and on‐target, inducible toxicity. Rapid clinical development of this method is promising as a new modality for treatment of pancreatic cancer.

show abstract

“…Proteome microarray Lung carcinoma Search for target protein [50] Proteome microarray Breast cancer Study on tumour microenvironment [51] Antibody microarray Metastatic colorectal cancer Study on the mechanism of drug resistance [52] Antibody microarray Gallbladder carcinoma Protein expression analysis [53] Antibody microarray Gastrointestinal stromal tumours Protein expression analysis [54] Antibody microarray Non-small-cell lung cancer Search for target protein [55] Antibody microarray Glioblastoma Study on the mechanism of drug resistance [56] Antibody Lectin microarray Cervical cancer Search for therapeutic targets [70] Lectin microarray Signet ring cell carcinoma Study on the mechanism of drug resistance Search for therapeutic targets [71] Lectin microarray Breast cancer Study on the mechanism of drug resistance [72] autoantibodies in serum samples of 50 GC patients and 30 healthy controls. Forty-four potential biomarkers were identified in this study.…”

Section: Types Of Array Cancer Type Application Referencementioning

confidence: 99%

Research progress in protein microarrays: Focussing on cancer research

Chen

Yang

Liu

et al. 2022

Proteomics Clinical Apps

View full text Add to dashboard Cite

Although several effective treatment modalities have been developed for cancers, the morbidity and mortality associated with cancer continues to increase every year. As one of the most exciting emerging technologies, protein microarrays represent a powerful tool in the field of cancer research because of their advantages such as high throughput, small sample usage, more flexibility, high sensitivity and direct readout of results. In this review, we focus on the research progress in four types of protein microarrays (proteome microarray, antibody microarray, lectin microarray and reversed protein array) with emphasis on their application in cancer research. Finally, we discuss the current challenges faced by protein microarrays and directions for future developments. We firmly believe that this novel systems biology research tool holds immense potential in cancer research and will become an irreplaceable tool in this field.

show abstract

Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy

Cited by 8 publications

References 33 publications

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: ¹⁸F‐labeled rBC2LCN lectin

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: ¹⁸F‐labeled rBC2LCN lectin

Lectin‐based phototherapy targeting cell surface glycans for pancreatic cancer

Research progress in protein microarrays: Focussing on cancer research

Contact Info

Product

Resources

About

Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy

Cited by 8 publications

References 33 publications

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18F‐labeled rBC2LCN lectin

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18F‐labeled rBC2LCN lectin

Lectin‐based phototherapy targeting cell surface glycans for pancreatic cancer

Research progress in protein microarrays: Focussing on cancer research

Contact Info

Product

Resources

About

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: ¹⁸F‐labeled rBC2LCN lectin

Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: ¹⁸F‐labeled rBC2LCN lectin